Literature DB >> 29472060

Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.

Jinping Yin1, Yu Zhang1, Yan Zhang1, Feng Peng2, You Lu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472060     DOI： 10.1016/j.jtho.2017.10.025

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation.

Authors:  Viola W Zhu; Alexa B Schrock; Thangavijayan Bosemani; Bryan S Benn; Siraj M Ali; Sai-Hong Ignatius Ou
Journal:  Lung Cancer (Auckl)       Date:  2018-11-08

2.  Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Authors:  Hong Tao; Zhe Liu; Jing Mu; Fei Gai; Zhan Huang; Liang Shi
Journal:  Diagn Pathol       Date:  2022-02-10       Impact factor: 2.644

3.  Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.

Authors:  Xueqian Wu; Weiya Wang; Bingwen Zou; Yanying Li; Xiaojuan Yang; Ning Liu; Qizhi Ma; Xiaoxuan Zhang; Yongsheng Wang; Dan Li
Journal:  Thorac Cancer       Date:  2020-03-24       Impact factor: 3.500
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.